Illimis Therapeutics
Seoul
About Illimis Therapeutics
Illimis Therapeutics is a platform-based biotech company that develops a chimeric fusion protein platform for neurodegenerative diseases. The company's proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $65.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2025)
- Website: illimistx.com
- Phone: +82 02 445 6877
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/illimis-therapeutics-81856 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.